Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:42:03.264Z.
Calculation as of: 2026-10-06T16:42:03.264Z.
Quote observation: 2026-10-06T16:40:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$667.57M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$692.10M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $667.57M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $669.96M | 3.81% | 10.03% | 6.88% | 6.20% |
| Helus Pharma Inc. (HELP)vs › | $675.63M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $677.62M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $656.00M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $685.14M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $692.10M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $633.99M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $701.42M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $630.75M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
